THC and CBD were safe but did not ease dementia-related agitation
A randomised, double-blind, placebo-controlled crossover trial on cannabinoid-based medication for behavioural disorders in old patients with severe dementia: the study results.
AI Summary
This randomised, double-blind, placebo-controlled crossover trial tested an oil containing THC and CBD in older adults with severe dementia and behavioural and psychological symptoms. Twenty-five patients, with an average age of 83, received the cannabinoid oil and placebo during separate 8-week treatment periods. The main outcome was agitation, assessed using the Cohen-Mansfield Agitation Inventory.
The THC/CBD oil did not significantly reduce agitation or other main behavioural symptoms compared with placebo. However, patients used significantly fewer as-needed psychotropic medications while receiving the cannabinoid treatment. The oil was well tolerated, with no serious study-drug-related adverse events reported. These findings suggest that cannabinoid medication may be a safe adjunct for selected patients, but the study does not show that it is superior to placebo for treating agitation in severe dementia.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More THC research papers you might find interesting.
Small lab study finds cannabis affected simulated driving and confidence
A lab method measures 17 cannabinoids across five hemp product types
A single-center study finds varied care and no recurrence in follow-up
Explore More Research
Stay informed about the latest cannabis science.